Melola Discovery

← Melola Discovery

Jurnal SINTA 1

The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study

ACTA MEDICA INDONESIANA · Vol. 51 No. 2 (2019)

ISSN
2338-2732, 0125-9326
Terbit
2019-08-05
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: HIV infection in HCV-infected patients accelerates disease progression and reduces the success rate of Peg-IFN/RBV treatment. HCV mutation in NS5A-ISDR/PKR-BD region improved the outcome in HCV monoinfection treated with Peg-IFN/RBV. SNP-IL28B polymorphism is predicted to have an effect on HCV quasispecies evolution. However, the role of NS5A mutation and SNP IL-28B in HIV-HCV coinfection is still unclear. The aim of the study is to determine the role of HCV NS5A-ISDR/PKR-BD mutation and SNP IL-28 polymorphism on the successfulness of Peg-IFN/RBV therapy in HCV-HIV coinfection. Methods: prospective cohort was performed in this study. Plasma sample were obtained from 30 and 8 patients with HCV-HIV coinfection and HCV monoinfection, respectively. PCR nucleotide sequencing was performed after RNA virus extraction and cDNA synthesis. Protein secondary structure and prediction of mutation function were analyzed using PredictProtein (PP) program. Results: sixteen HCV-HIV coinfected patients and none from eight HCV patients achieved sustained virological response (SVR). ≥1 non-neutral mutation was found in 24/30 HCV-HIV coinfection and more frequent in SVR group (14 patients). ≥1 non-neutral mutation were found statistically significant for overall SVR achievement (p<0.05) in all patients regardless of coinfection or monoinfection status. Of the 27 HCV-HIV coinfected patients with CC-gene, 21 subjects had non-neutral mutation. The structure which was expected as NS5A binding site structure was different from consensus (wild type) in SVR group, while the structure was similar to consensus in non-SVR group. Conclusion: having ≥1 non-neutral mutation was associated with SVR achievement in Peg-IFN/RBV therapy, regardless of monoinfection and coinfection status.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 265 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Siti SetiatiAfiliasi tidak diketahui14
Irsan HasanAfiliasi tidak diketahui10
Evy YunihastutiAfiliasi tidak diketahui9
Idrus AlwiAfiliasi tidak diketahui8
Rino Alvani GaniAfiliasi tidak diketahui6
Rudi PutrantoAfiliasi tidak diketahui6
Noto DwimartutieAfiliasi tidak diketahui5
Andri Sanityoso SulaimanAfiliasi tidak diketahui5
Chyntia Olivia Maurine JasirwanAfiliasi tidak diketahui5
Kemal Fariz KalistaAfiliasi tidak diketahui5
Suhendro SuwartoAfiliasi tidak diketahui5
Imam SubektiAfiliasi tidak diketahui5
Roza MulyanaAfiliasi tidak diketahui4
Eka Dian SafitriAfiliasi tidak diketahui4
Rahmi IstantiAfiliasi tidak diketahui4
Taufik IndrajayaAfiliasi tidak diketahui4
Hamzah ShatriAfiliasi tidak diketahui4
Birry KarimAfiliasi tidak diketahui4
Iris RengganisAfiliasi tidak diketahui4
Cleopas Martin RumendeAfiliasi tidak diketahui4
Lutfie LutfieAfiliasi tidak diketahui3
Cosmas Rinaldi A LesmanaAfiliasi tidak diketahui3
Eka GinanjarAfiliasi tidak diketahui3
Suzanna ImmanuelAfiliasi tidak diketahui3
Aida LydiaAfiliasi tidak diketahui3
Respati W RanakusumaAfiliasi tidak diketahui3
Siti Rizny F SaldiAfiliasi tidak diketahui3
Jessica MarsigitAfiliasi tidak diketahui3
Ika P WijayaAfiliasi tidak diketahui3
Andri SanityosoAfiliasi tidak diketahui3
Sally Aman NasutionAfiliasi tidak diketahui3
Dyah PurnamasariAfiliasi tidak diketahui3
Pradana SoewondoAfiliasi tidak diketahui3

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study</dc:title>
	<dc:creator>Kurniawan, Juferdy</dc:creator>
	<dc:creator>Gani, Rino A</dc:creator>
	<dc:creator>Djauzi, Samsuridjal</dc:creator>
	<dc:creator>Ibrahim, Fera</dc:creator>
	<dc:creator>Harimurti, Kuntjoro</dc:creator>
	<dc:creator>nafrialdi, nafrialdi</dc:creator>
	<dc:creator>Imannuel, Suzanna</dc:creator>
	<dc:subject xml:lang="en-US">NS5A-ISDR/PKR-BD</dc:subject>
	<dc:subject xml:lang="en-US">SNP IL-28B</dc:subject>
	<dc:subject xml:lang="en-US">HCV-HIV coinfection</dc:subject>
	<dc:subject xml:lang="en-US">nonneutral mutation</dc:subject>
	<dc:subject xml:lang="en-US">SVR</dc:subject>
	<dc:description xml:lang="en-US">Background: HIV infection in HCV-infected patients accelerates disease progression and reduces the success rate of Peg-IFN/RBV treatment. HCV mutation in NS5A-ISDR/PKR-BD region improved the outcome in HCV monoinfection treated with Peg-IFN/RBV. SNP-IL28B polymorphism is predicted to have an effect on HCV quasispecies evolution. However, the role of NS5A mutation and SNP IL-28B in HIV-HCV coinfection is still unclear. The aim of the study is to determine the role of HCV NS5A-ISDR/PKR-BD mutation and SNP IL-28 polymorphism on the successfulness of Peg-IFN/RBV therapy in HCV-HIV coinfection. Methods: prospective cohort was performed in this study. Plasma sample were obtained from 30 and 8 patients with HCV-HIV coinfection and HCV monoinfection, respectively. PCR nucleotide sequencing was performed after RNA virus extraction and cDNA synthesis. Protein secondary structure and prediction of mutation function were analyzed using PredictProtein (PP) program. Results: sixteen HCV-HIV coinfected patients and none from eight HCV patients achieved sustained virological response (SVR). ≥1 non-neutral mutation was found in 24/30 HCV-HIV coinfection and more frequent in SVR group (14 patients). ≥1 non-neutral mutation were found statistically significant for overall SVR achievement (p&amp;lt;0.05) in all patients regardless of coinfection or monoinfection status. Of the 27 HCV-HIV coinfected patients with CC-gene, 21 subjects had non-neutral mutation. The structure which was expected as NS5A binding site structure was different from consensus (wild type) in SVR group, while the structure was similar to consensus in non-SVR group. Conclusion: having ≥1 non-neutral mutation was associated with SVR achievement in Peg-IFN/RBV therapy, regardless of monoinfection and coinfection status.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2019-08-05</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/1061</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 51 No. 2 (2019): Acta Medica Indonesiana; 128</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/1061/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2019 Acta Medica Indonesiana</dc:rights>
</oai_dc:dc>